Purpose/introduction: Conflicting results have been published regarding the effect of abnormal glucose metabolism on osteoporosis (AGM). Fasting glucose is a reliable indicator for abnormal glucose metabolism. Therefore, the aim of present study is to identify the association of fasting glucose level with the risk of incident osteoporosis.
Methods: In a cohort of 59,936 men and 36,690 women (mean age of 63.9 ± 7.1 years) registered in national health insurance database, we assessed the risk of incident osteoporosis according to the quartile levels of baseline fasting glucose (quartile 1: <88 mg/dL, quartile 2: 88-96 mg/dL, quartile 3: 97-107 mg/dL and quartile 4: ≥108 mg/dL) and glycemic status categorized into normal, impaired fasting glucose (IFG) and diabetes mellitus (DM). Multivariate Cox-proportional hazard model was used in calculating adjusted hazard ratios (HRs) and 95% confidence interval (CI) for incident osteoporosis (adjusted HRs [95% CI]).
Results: Compared with first quartile (reference), the risk of osteoporosis significantly decreased above the fourth quartile in men (second quartile: 1.04 [0.91-1.18], third quartile: 0.88 (0.76-1.00) and fourth quartile: 0.80 [0.70-0.92]) and above third quartile in women (second quartile: 0.95 [0.90-1.01], third quartile: 0.91 [0.86-0.97] and fourth quartile: 0.82 [0.77-0.88]). The risk of osteoporosis was less associated with IFG (men: 0.84 [0.76-0.94] and women: 0.93 [0.89-0.98]) and DM (men: 0.77 [0.65-0.91] and women: 0.75 [0.69-0.81]) than normal glucose group in both men and women.
Conclusion: Our results suggest that elevated fasting glucose potentially associated with the decreased risk of osteoporosis.
Mini-abstract: This retrospective study investigated the association between fasting glucose level and incidence of osteoporosis. Our findings indicate that elevated fasting glucose is significantly associated with the decreased risk of osteoporosis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bone.2020.115690 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prevalence and predictive risk factors of hypertensive disorders in pregnant women at high risk for gestational diabetes. The PREeclampsia in DIabetiC gestaTION (PREDICTION) study.
J Endocrinol Invest
January 2025
Department of Medical Area, Section of Metabolic Diseases and Diabetes, University Hospital of Pisa, Via Paradisa, 2, Pisa, 56124, Italy.
Purpose: Women with gestational diabetes (GDM) have increased risk of hypertensive disorders in pregnancy (HDP). However, knowledge remains limited for women with high-risk metabolic profiles, regardless of GDM diagnosis. This study aimed to evaluate the prevalence of HDP among women at high risk for GDM, while simultaneously identifying potential predictive clinical risk factors of HDP.
View Article and Find Full Text PDFPuerarin Attenuates Podocyte Damage in Mice With Diabetic Kidney Disease by Modulating the AMPK/Nrf2 Pathway.
Int J Endocrinol
January 2025
Nephrology Department, Jiangxi Provincial Key Research Laboratory of Traditional Chinese Medicine, Key Research Laboratory of Chronic Renal Failure, Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine, Nanchang, Jiangxi 330006, China.
This study aimed to investigate the potential mechanisms of puerarin in alleviating diabetic nephropathy (DKD) in mice. The DKD model was induced by multiple low-dose injections of streptozotocin (STZ) and a high-sugar and high-fat diet in male C57BL/6J mice. After confirming the onset of DKD, mice were given irbesartan, distilled water, or different concentrations of puerarin (40 and 80 mg/kg/d) by gavage for 8 weeks.
View Article and Find Full Text PDFEffects of vitamin D supplementation on the glycaemic indices, lipid profile and liver function tests in patients with cirrhosis: a double-blind randomised controlled trial.
BMJ Nutr Prev Health
August 2024
Health Research Center, Life Style Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Background: Liver cirrhosis is considered a progressive disease that can eventually result in death. Vitamin D deficiency is prevalent in patients with cirrhosis. Few studies have been conducted on the effect of vitamin D supplementation in patients with cirrhosis.
View Article and Find Full Text PDFDietary variety score and risk of metabolic syndrome incidence: Tehran Lipid and Glucose Study.
BMJ Nutr Prev Health
August 2024
Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Purpose: There are contradictions in the association between dietary variety and metabolic syndrome (MetS). The concept of dietary variety should be merged with other dietary recommendations including diet quality and proportion. We aimed to investigate the association of the healthy food diversity index with MetS and its components in Iranian adults.
View Article and Find Full Text PDFEffectiveness of Oral Semaglutide in Management of Type 2 Diabetes: A Real-World Study from India.
Indian J Endocrinol Metab
December 2024
Department of Endocrinology, Max Super Speciality Hospital, Saket, New Delhi, India.
Introduction: Oral Semaglutide (Sema-o) is the first oral glucagon like peptide-1 receptor analogue (GLP-1RA) commercially available for the treatment of type 2 diabetes (T2D). This study aimed to evaluate the efficacy of Sema-o in patients with T2D when added to the existing therapy.
Methods: This retrospective real-world study enrolled adult patients with diabetes taking Sema-o, with at least one follow-up (from February 2022 till October 2023).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!